The FDA has approved Nuvaxovid, a recombinant protein-based COVID-19 vaccine, for use in adults aged 65 and older and individuals aged 12 through 64 with underlying conditions linked to severe COVID-19. It is the only non-mRNA COVID-19 vaccine available in the U.S. Novavax, the manufacturer, will receive a milestone payment from Sanofi and is eligible for ongoing royalties. Postmarketing commitments and adverse events have been outlined, including contraindications and reduced efficacy in immunocompromised patients.

Source: Novavax Inc.